Thaksaporn Thatsanatorn
Overview
Explore the profile of Thaksaporn Thatsanatorn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
260
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pratedrat P, Intharasongkroh D, Chansaenroj J, Vichaiwattana P, Srimuan D, Thatsanatorn T, et al.
Diseases
. 2023 Sep;
11(3).
PMID: 37754308
Coronavirus disease 2019 (COVID-19) is a contagious illness worldwide. While guidelines for the treatment of COVID-19 have been established, the understanding of the relationship among neutralizing antibodies, cytokines, and the...
2.
Wanlapakorn N, Kanokudom S, Phowatthanasathian H, Chansaenroj J, Suntronwong N, Assawakosri S, et al.
J Med Virol
. 2023 May;
95(5):e28758.
PMID: 37212319
To compare the reactogenicity and immunogenicity between the two-dose mRNA COVID-19 vaccine regimen and one or two doses of inactivated vaccine followed by an mRNA vaccine regimen in healthy children...
3.
Suntronwong N, Vichaiwattana P, Klinfueng S, Puenpa J, Kanokudom S, Assawakosri S, et al.
PLoS One
. 2023 Apr;
18(4):e0279147.
PMID: 37104299
Background: Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection can be asymptomatic in young children. Therefore, the true rate of infection is likely underestimated. Few data are available on the rate of...
4.
Kanokudom S, Chansaenroj J, Suntronwong N, Assawakosri S, Yorsaeng R, Nilyanimit P, et al.
Int J Infect Dis
. 2022 Nov;
126:64-72.
PMID: 36427701
Objectives: To report the safety and immunogenicity profile of a protein subunit vaccine (Covovax) given as a third (booster) dose to individuals primed with different primary vaccine regimens. Methods: A...
5.
Kanokudom S, Assawakosri S, Suntronwong N, Chansaenroj J, Auphimai C, Nilyanimit P, et al.
Vaccine
. 2022 Aug;
40(39):5657-5663.
PMID: 36031500
The coronavirus disease 2019 (COVID-19) pandemic has been a serious healthcare problem worldwide since December 2019. The third dose of heterologous vaccine was recently approved by World Health Organization. The...
6.
Suntronwong N, Kanokudom S, Auphimai C, Assawakosri S, Thongmee T, Vichaiwattana P, et al.
J Med Virol
. 2022 Aug;
94(12):5713-5722.
PMID: 35924475
The coronavirus 2019 omicron variant has surged rapidly and raises concerns about immune evasion even in individuals with complete vaccination, because it harbors mutations. Here we examine the capability of...
7.
Suntronwong N, Assawakosri S, Kanokudom S, Yorsaeng R, Auphimai C, Thongmee T, et al.
Diagnostics (Basel)
. 2022 Jul;
12(8).
PMID: 35892491
This study examined the neutralizing activity and receptor-binding domain (RBD) antibody levels against wild-type and omicron BA.1 and BA.2 variants in individuals who received three doses of COVID-19 vaccination. The...
8.
Chansaenroj J, Suntronwong N, Kanokudom S, Assawakosri S, Yorsaeng R, Vichaiwattana P, et al.
Vaccines (Basel)
. 2022 Jul;
10(7).
PMID: 35891235
Coronavirus disease 2019 (COVID-19) booster vaccination is being comprehensively evaluated globally due to waning immunity and the emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. Therefore, this...
9.
Assawakosri S, Kanokudom S, Chansaenroj J, Suntronwong N, Auphimai C, Nilyanimit P, et al.
Int J Infect Dis
. 2022 Jul;
122:793-801.
PMID: 35863731
Objectives: The SARS-CoV-2 Omicron variant presents numerous mutations potentially able to evade neutralizing antibodies (NAbs) elicited by COVID-19 vaccines. Therefore, this study aimed to provide evidence on a heterologous booster...
10.
Suntronwong N, Yorsaeng R, Puenpa J, Auphimai C, Thongmee T, Vichaiwattana P, et al.
Vaccines (Basel)
. 2022 Mar;
10(3).
PMID: 35335023
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and the waning of immunity in vaccinated individuals is resulting in increased numbers of SARS-CoV-2 breakthrough infections. This study...